Role of PGE-type receptor 4 in auditory function and noise-induced hearing loss in mice  by Hamaguchi, Kiyomi et al.
at SciVerse ScienceDirect
Neuropharmacology 62 (2012) 1841e1847Contents lists availableNeuropharmacology
journal homepage: www.elsevier .com/locate/neuropharmRole of PGE-type receptor 4 in auditory function and noise-induced hearing
loss in mice
Kiyomi Hamaguchi a, Norio Yamamoto a, Takayuki Nakagawa a,*, Tomoyuki Furuyashiki b,c,
Shuh Narumiya b,c, Juichi Ito a
aDepartment of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kawaharacho 54, Shogoin, Sakyoku, Kyoto 606-8507, Japan
bDepartment of Pharmacology, Kyoto University Faculty of Medicine, Kyoto 606-8501, Japan
c Japan Science and Technology Agency, Core Research for Evolutional Science and Technology (CREST), Kyoto 606-8501, Japana r t i c l e i n f o
Article history:
Received 28 September 2011
Received in revised form
16 November 2011






PGE-type receptorAbbreviations: DAPI, 40 ,6-diamino-2-phenyl-indo
response; EP, E-prostanoid receptors; PGE2, prostagla
ANOVA, analysis of variance; DMSO, dimethyl su
product otoacoustic emissions; H&E, hematoxylin and
NF, noise ﬂoor; OHCs, outer hair cells; RWM, round wi
pressure level.
* Corresponding author. Tel.: þ81 75 751 3346; fax
E-mail address: tnakagawa@ent.kuhp.kyoto-u.ac.jp
0028-3908  2011 Elsevier Ltd.
doi:10.1016/j.neuropharm.2011.12.007
Open access under CC Ba b s t r a c t
This study explored the physiological roles of PGE-type receptor 4 (EP4) in auditory function. EP4-
deﬁcient mice exhibited slight hearing loss and a reduction of distortion-product otoacoustic emis-
sions (DPOAEs) with loss of outer hair cells (OHCs) in cochleae. After exposure to intense noise, these
mice showed signiﬁcantly larger threshold shifts of auditory brainestem responses (ABRs) and greater
reductions of DPOAEs than wild-type mice. A signiﬁcant increase of OHC loss was conﬁrmed morpho-
logically in the cochleae of EP4-deﬁcient mice. Pharmacological inhibition of EP4 had a similar effect to
genetic deletion, causing loss of both hearing and OHCs in C57BL/6 mice, indicating a critical role for EP4
signaling in the maintenance of auditory function. Pharmacological activation of EP4 signiﬁcantly pro-
tected OHCs against noise trauma, and attenuated noise-induced hearing loss in C57BL/6 mice. These
ﬁndings suggest that EP4 signaling is necessary for the maintenance of cochlear physiological function
and for cochlear protection against noise-induced damage, in particular OHCs. EP4 might therefore be an
effective target for cochlear disease therapeutics.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Prostaglandins (PGs) are short-lived potent bioactive lipid
messengers belonging to the family of eicosanoids, and are
involved in numerous physiological reactions (Funk, 2001; Harris
et al., 2002; Simmons et al., 2004; Smith et al., 2000). Prosta-
glandin E2 (PGE2) is the most abundant prostanoid in humans, and
is involved in the regulation of various fundamental biological
functions including hemodynamics and inﬂammation (Legler et al.,
2010; Narumiya, 2007). The divergent effects of PGE2 signaling
probably depend on the distinct patterns and dynamics of the
expression of PGE receptors, particularly E-prostanoid receptors
1e4 (EP1e4) (Sugimoto and Narumiya, 2007). For example, inle; ABR, auditory brainstem
ndin E2; PGs, prostaglandins;
lfoxide; DPOAEs, distortion-
eosin; IHCs, inner hair cells;
ndow membrane; SPL, sound
: þ81 75 751 7225.
(T. Nakagawa).
Y-NC-ND license.hemodynamics, EP1 induces vasoconstriction in the peripheral
vasculature, whereas EP2 and EP4 induce vasodilation.
There is growing evidence that individual EP signaling plays
signiﬁcant roles in neurodegenerative diseases (Andreasson, 2010).
Although some subtype-speciﬁc EP signaling events mediate toxic
effects in the central nervous system, others paradoxically appear
to mediate protective effects (Andreasson, 2010). EP4 signaling has
been reported to provide neuroprotective effects in excitotoxic
(Ahmad et al., 2005) and ischemic (Li et al., 2008) models, and, in
some contexts, to mediate an anti-inﬂammatory effect (Esaki et al.,
2010; Shi et al., 2010). Pharmacological inhibition of EP4 signaling
reverses the attenuation of spinal cord injury caused by PGE1
analogs (Umemura et al., 2010). These ﬁndings in the central
nervous system encouraged us to investigate the roles of EP4
signaling in the auditory system.
In the inner ear, PGs have attracted particular attention as regu-
lators of the cochlear blood ﬂow (Rhee et al., 1999; Tominaga et al.,
2006; Umemura et al., 1990), and disorders of this blood ﬂow have
been considered a principle cause of sudden deafness (Nakashima
et al., 2003). This has resulted in the clinical use of PGE1 in the
treatment of sudden deafness, although little is known about the
roles of PGE2eEP signaling in auditory function (Nakagawa, 2011).
Previous studies have demonstrated that PGE2 is constitutively
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are expressed in various types of cochlear cell (Hori et al., 2009, 2010;
Stjernschantz et al., 2004), suggesting that EP signaling might play
roles in the physiology and pathophysiology of the cochlea. The
present study focused on EP4 because of its reported protective
effects onneurons against neuronal degeneration in various contexts
(Ahmad et al., 2005; Esaki et al., 2010; Li et al., 2008; Shi et al., 2010;
Umemura et al., 2010).
In the current study, we evaluated the functionality and
morphology of cochleae in EP4-deﬁcient mice under physiological
conditions or following noise exposure. Pharmacological inhibition
or activation of EP4 signaling was examined using mousemodels of
noise-induced hearing loss in order to conﬁrm the ﬁndings.
2. Materials and methods
2.1. Animals and reagents
EP4-deﬁcient mice were generated as described previously (Segi et al., 1998).
Most EP4-deﬁcient mice die postnatally as a result of patent ductus arteriosus and
do not survive on a C57BL/6 background (Nguyen et al., 1997; Segi et al., 1998). Male
EP4-deﬁcient mice with a mixed 129/Ola and C57BL/6 genetic background
(Kabashima et al., 2002) aged 8 weeks were used. Male mice with a similar mixed
genetic background to the EP4-deﬁcient mice were used as wild-type animals. The
pharmacological inhibition and enhancement of EP4 signaling were investigated
using 8-week-old male C57BL/6 mice (Japan SLC, Inc., Hamamatsu, Japan).
Animals were maintained at the Institute of Laboratory Animals, Kyoto
University, Japan, under a 12-h light/12-h dark cycle and speciﬁc pathogen-free
conditions. Mice were fed ad libitum with standard chow. Bedding and water
bottles were replaced daily. The Animal Research Committee of the Graduate School
of Medicine, Kyoto University, approved all experimental protocols.
The EP4 antagonist ONO-AE3-208 and the EP4 agonist ONO-AE1-329 were
supplied by Ono Pharmaceutical, Co., Ltd (Osaka, Japan). Rabbit anti-bIII tubulin
antibody was purchased from Covance Research Products (Berkeley, CA). Rabbit
anti-myosin VIIa polyclonal antibody was purchased from Proteus BioSciences
(Ramona, CA). Alexa 488 or 568-conjugated goat anti-rabbit antibody, DAPI, and
ﬂuoresceinephalloidin were purchased from Molecular Probes (Eugene, OR). Rabbit
anti-EP4 receptor polyclonal antibody was purchased from Caymann Chemical (Ann
Arbor, MI).
2.2. Auditory brainstem response (ABR)
Measurements of ABRs have been performed as described previously (Kada
et al., 2009). Thresholds were determined for frequencies of 10, 20, and 40 kHz
from a set of responses at varying intensities with 5-dB sound pressure level (SPL)
intervals. When no response was present at the highest sound level available, the
threshold was designated as being 5 dB greater than that level for statistical
purposes. The thresholds at each frequency were veriﬁed at least twice.
2.3. Distortion-product otoacoustic emissions (DPOAEs)
Recordings were made with an acoustic probe (ER-10C; Etymotic Research, Elk
Grove Village, IL) using the DP2000 DPOAE measurement system version 3.0
(Starkey Laboratory, Eden Prairie, MN). Two primary tones with an f2/f1 ratio of 1.2
were presented at intensity levels of 65 dB SPL (L1) and 55 dB SPL (L2). The f2 was
varied in one-ninth-octave steps from 8 to 16 kHz. A peak at 2f1ef2 in the spectrum
was recognized as a DPOAE. The DP/noise ﬂoor (NF) levels were calculated and
statistical analyses were performed at each f2 frequency.
2.4. Endocochlear potential
Measurements of the endocochlear potential were performed as described
previously (Kada et al., 2009). A silveresilver chloride reference electrodewas placed
under the skin of the dorsum. A micropipette electrode (10e40 MO) ﬁlled with
150 mM KCl was advanced through the bony aperture into the spiral ligament. The
entry of the electrode tip into the endolymphwas characterized by fast changes of the
recordedpotentials. Theelectrodewas advanceduntil a stablepotentialwasobserved,
at which point no alterations were dependent upon its depth. The signal was passed
through an ampliﬁer (Duo 773; World Precision Instruments, Sarasota, FL).
2.5. Surgical procedure for topical application
The EP4 antagonist ONO-AE3-208 was dissolved in 1 N NaOH and diluted with
PBS to give a ﬁnal concentration of 1 mg/ml and a ﬁnal pH of 7.4. The EP4 agonist
ONO-AE1-329 was dissolved in DMSO and diluted with physiological saline to give
a ﬁnal concentration of 1 mg/ml containing 1% dimethyl sulfoxide (DMSO). Bothdrugs were applied topically under general anesthesia. The otic bulla of the left
temporal bone was exposed via a retroauricular approach. A small hole was made in
the otic bulla to access the round window membrane (RWM). A dry gelatin sponge
was cut into 0.5e1 mm3 pieces and a piece of the sponge placed on the RWM
following the immersion of substrates (2 ml). Control animals received topical
application of PBS at pH 7.4 or physiological saline containing 1% DMSO.
2.6. Noise exposure
Animals under general anesthesia were placed in a ventilated sound-exposure
chamber ﬁtted with speakers driven by a noise generator and a power ampliﬁer.
A 1/2-inch condenser microphone and a fast Fourier transform analyzer (both from
Sony, Tokyo, Japan) were used to monitor and calibrate sound levels at multiple
locations within the chamber, in order to ensure uniformity of the stimulus. The
stimulus intensity varied by a maximum of 3 dB SPL across measured sites within
the exposure chamber.
2.7. Histology
After the functional analyses, the cochleae were subjected to histological anal-
ysis as whole mounts or 10-mm-thick frozen sections. The whole-mount samples
were used for the histological evaluation of hair cells. The frozen sections were used
for the evaluation of gross anatomy by hematoxylin and eosin (H&E) staining, for
immunohistochemistry for EP4 or for quantitative assessments of spiral ganglion
neurons.
The whole-mount specimens were separated into three regions with distances
from the apex of 20e40% (corresponding to 8e16 kHz regions; apical portion),
40e70% (corresponding to 16e32 kHz regions; mid-basal portion), and 70e90%
(corresponding to 32e64 kHz regions; basal portion) (Viberg and Canlon, 2004).
After permeabilizationwith 0.2% Triton X in PBS for 30min at room temperature, the
specimens were incubated with anti-myosin VIIa rabbit polyclonal antibody (1:500)
for 12 h at 4 C, followed by incubation with Alexa-568 conjugated anti-rabbit goat
IgG (1:500) secondary antibody. At the end of the staining procedures, the speci-
mens were stained with ﬂuoresceinephalloidin (1:400) and 40 ,6-diamino-2-phenyl-
indole (DAPI) for 15 min at room temperature, and viewed with a confocal micro-
scope (TCS SPE; Leica Microsystems, Wetzlar, Germany). The respective numbers of
inner hair cells (IHCs) and outer hair cells (OHCs) were counted, and the ratio of
missing IHCs and OHCs was calculated for each region of cochleae.
Two mid-modiolar sections (separated by a distance of 40e50 mm) from each
cochlea were used for immunostaining for EP4 or for the histological analysis of
spiral ganglion neurons, respectively. Immunohistochemistry for EP4 was per-
formed with anti-EP4 receptor (1:200) primary antibody and Alexa 568-conjugated
anti-rabbit goat IgG (1:500) secondary antibody. Immunohistochemistry for bIII-
tubulin was performed to identify the spiral ganglion neurons in the Rosenthal’s
canal. Specimens were treatedwith rabbit anti-bIII tubulin (1:250) primary antibody
and Alexa-488 conjugated anti-rabbit goat IgG (1:500) secondary antibody, followed
by nuclear labeling with DAPI. The specimens were then observed using a ﬂuores-
cence microscope (Olympus BX50, Tokyo, Japan). The numbers of spiral ganglion
neurons and the area of the Rosenthal’s canal were quantiﬁed, and the density of
spiral ganglion neurons was calculated as described previously (Kada et al., 2009).
2.8. Statistical analysis
Data are expressed as themean SEM for the indicated number of observations.
The unpaired Student’s t-test (two-tailed) was used, as appropriate, for comparisons
between two groups. Two-way factorial analysis of variance (ANOVA) was used for
comparisons of ABR-threshold shifts after noise exposure, and the TukeyeKramer
test was performed for pair-wise comparisons. P < 0.05 was considered statistically
signiﬁcant.3. Results
3.1. Hearing loss in EP4-deﬁcient mice
ABR recordings for screening the auditory function of EP4-
deﬁcient mice demonstrated signiﬁcant but slight hearing loss at
frequencies of 10, 20, and 40 kHz. EP4-deﬁcient mice (n ¼ 16)
exhibited signiﬁcant elevation of ABR thresholds in comparison
with wild-type mice (n ¼ 16) at 10 kHz (P < 0.0001), 20 kHz
(P < 0.0001), and 40 kHz (P < 0.0001) (Fig. 1A). To examine the
mechanisms underlying the hearing impairment in EP4-deﬁcient
mice, we measured DPOAEs, which reﬂect the OHCs in the
cochlea (Parham et al., 1999), and the endocochlear potential,
which is the positive voltage in the endolymphatic space of the
Fig. 1. Auditory function and cochlear morphology of EP4-deﬁcient mice. (A) The ABR thresholds in EP4-deﬁcient mice differed signiﬁcantly at each frequency in comparison with
those in wild-type mice. Asterisk indicates a signiﬁcant difference (P < 0.05). (B) The DP/NF levels of EP4-deﬁcient mice were signiﬁcantly lower than those of wild-type mice at f2
frequencies of 15,984 and 14,672 Hz. Asterisk indicates a signiﬁcant difference (P < 0.05). (C) No statistical difference in the endocochlear potential was found between EP4-deﬁcient
and wild-type mice. (D) Immunostaining for EP4 (red) and nuclear staining with DAPI (blue) showed EP4 expression in an inner hair cell (I) and outer hair cells (O) of the organ of
Corti, spiral ganglion neurons and stria vascularis in a wild-type cochlea, while no expression was found in an EP4-deﬁcient cochlea. Scale bar, 50 mm. (E) H&E staining of a cross
section of an EP4-deﬁcient cochlea revealed no abnormalities. OC, organ of Corti; RM, Reissner’s membrane; SGN, spiral ganglion neuron; SV, stria vascularis. Scale bars, 200 mm.
(F) Immunostaining for myosin VIIa (red) and F-actin labeling with phalloidin (green) revealed loss of OHCs in EP4-deﬁcient mice (asterisked). Scale bar, 50 mm. (G) The percentages
of OHC loss in each part of cochleae in EP4-deﬁcient and wild-type mice are shown. (H) No signiﬁcant differences in the densities of spiral ganglion neuron (SGN) were found in the
apical (Ap), mid-basal (mB) or basal (Bs) portions of cochleae between EP4-deﬁcient and wild-type mice. In all graphs, the error bars represent the SEM. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Spyropoulos, 1959).
In DPOAE measurements, EP4-deﬁcient animals demonstrated
signiﬁcant loss in the DP/NF levels at f2 frequencies of 14,672
(P < 0.0001) and 15,984 Hz (P ¼ 0.0255) compared with wild-type
animals (n ¼ 16 for each; Fig. 1B). By contrast, the mean endoco-
chlear potential of the EP4-deﬁcient mice (107.3  6.5 mV) did not
differ signiﬁcantly from that ofwild-typemice (104.8 5.1mV; n¼4
for each; Fig. 1C). These functional assessments suggested that the
EP4-deﬁcient mice had slight hearing loss due to OHC dysfunction.
To investigate the morphological phenotypes of the EP4-
deﬁcient mice, cochlear specimens were examined using either
cryostat sections or surface preparations. The expression of EP4was
found in in the stria vascularis, spiral ganglion neurons, supporting
cells, IHCs and OHCs in wild-type mice (Fig. 1D) similarly to ourprevious observation (Hori et al., 2009), while no expression of EP4
was identiﬁed in EP4-deﬁcient mice (Fig. 1D). H&E staining of cross
sections revealed that the gross anatomy of EP4-deﬁcient mice
cochleae was essentially normal (Fig. 1E). No apparent degenera-
tion was seen in the organ of Corti, spiral ganglion, or cochlear
lateral wall including the stria vascularis at the light-microscopic
level. Immunostaining for myosin VIIa and f-actin labeling with
phalloidin revealed the surface morphology of the organ of Corti.
Loss of OHCs was observed in the basal, mid-basal, and apical
portions of EP4-deﬁcient cochleae (Fig.1F). OHC loss was conﬁrmed
by the nuclear staining with DAPI. However, there was no statisti-
cally signiﬁcant difference in OHC loss between EP4-deﬁcient and
wild-type mice (Fig. 1G). This ﬁnding suggested an involvement of
other mechanisms besides OHC degeneration for hearing loss in
EP4-deﬁcient mice. We then quantitatively analyzed the density of
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using immunostaining for bIII tubulin in cross sections, which
showed no signiﬁcant loss of spiral ganglion neurons (Fig. 1H). We
therefore considered that EP4 deﬁciency affected auditory systems
including OHC function, which might result in modest hearing loss
under physiological conditions.
3.2. Vulnerability to noise trauma in EP4-deﬁcient mice
Mouse models of noise-induced hearing loss have previously
beenused to test the roles of variousmolecules inpathophysiological
conditionsof theauditorysystem(Peppi et al., 2011; Polesskaya et al.,
2010; Tan et al., 2010). Noise-induced damage sometimes clariﬁed
roles of molecules in auditory function. We therefore examined the
effects of EP4 deﬁciency on noise-induced hearing loss, in order to
clarify its role in auditory function. EP4-deﬁcient andwild-typemice
(n¼ 12 for each) were exposed to an octave-band noise centered on
8 kHz at a 120-dB SPL for 2 h, and then subjected to ABRFig. 2. Vulnerability of EP4-deﬁcient mice to noise trauma (an octave-band noise centered
threshold shifts of EP4-deﬁcient and wild-type mice at frequencies of 10, 20, and 40 kH
statistically signiﬁcant at all frequencies. Asterisks indicate signiﬁcant differences in ABR-t
EP4-deﬁcient mice were observed at 11,297, 13,453, 14,672 and 15,984 Hz. Asterisk indicates
was similar to that in wild-type mice after noise trauma. (D) Immunostaining for myosin VI
each cochlear portion of EP4-deﬁcient mice (asterisked). Scale bar, 20 mm. (E) EP4-deﬁcient
and basal (Bs) portions of cochleae compared with wild-type mice. Asterisk indicates a sig
staining for DAPI (blue) revealed the spiral ganglion neurons of EP4-deﬁcient mice to be no
ganglion neurons (SGN) between EP4-deﬁcient and wild-type mice. In all graphs, the erro
legend, the reader is referred to the web version of this article.)measurements 7 and 14 days later. Alterations in the ABR-threshold
shifts of EP4-deﬁcient and wild-type mice are shown in Fig. 2A. The
overall effects of EP4 deﬁciency on the ABR-threshold shifts were
statistically signiﬁcant at 10 kHz (df ¼ 1, F ¼ 5.287 and P ¼ 0.0247),
20 kHz (df ¼ 1, F ¼ 10.720 and P ¼ 0.0017), and 40 kHz (df ¼ 1,
F¼ 17.323 and P< 0.0001)with two-way factorial ANOVA. Pair-wise
comparisons with TukeyeKramer test revealed signiﬁcantly higher
elevations of ABR thresholds in EP4-deﬁcient than inwild-typemice
on day 14 at 20 kHz, and on days 7 and 14 at 40 kHz. DPOAE
assessments demonstrated signiﬁcant decreases of DP/NF levels at
11,297 Hz (P ¼ 0.0005), 13,453 Hz (P ¼ 0.0068), 14,672 Hz
(P ¼ 0.0371), and 15,984 Hz (P ¼ 0.0006) in EP4-deﬁcient mice
compared with wild-type mice (Fig. 2B). These ﬁndings demon-
strated that noise exposure revealed auditory system differences
between EP4-deﬁcient and wild-type mice, in particular high
frequency regions. By contrast, therewas no signiﬁcant difference in
the endocochlear potential between EP4-deﬁcient (103.3  2.5 mV)
and wild-type (97.3  3.5 mV) mice (Fig. 2C).on 8 kHz at a 120-dB SPL for 2 h). (A) The time courses of the alterations in the ABR-
z are shown. The overall effects of EP4 deﬁciency on the ABR-threshold shifts were
hreshold shifts in pair-wise comparisons. (B) Signiﬁcant decreases in DP/NF levels in
a signiﬁcant difference (P < 0.05). (C) The endocochlear potential in EP4-deﬁcient mice
Ia (red) and F-actin labeling with phalloidin (green) revealed extensive loss of OHCs in
mice showed signiﬁcantly higher levels of OHC loss in the apical (Ap), mid-basal (mB),
niﬁcant difference (P < 0.05). (F) Immunostaining for bIII-tubulin (green) and nuclear
rmal. Scale bar, 50 mm. (G) There was no signiﬁcant difference in the density of spiral
r bars represent the SEM. (For interpretation of the references to colour in this ﬁgure
Fig. 3. Pharmacological inhibition of EP4 accelerated noise-induced damage in
cochleae. The EP4 antagonist ONO-AE3-208 was topically applied to the RWM and
control mice received a topical application of PBS at pH 7.4. (A) The time courses of the
alterations in the ABR-threshold shifts of EP4 antagonist-treated and control mice at
frequencies of 10, 20, and 40 kHz are shown. The overall effects of EP4 antagonist
application were signiﬁcant at all frequencies. Asterisks indicate signiﬁcant differences
in ABR-threshold shifts between EP4 antagonist-treated and control mice with pair-
wise comparisons. (B) Immunostaining for myosin VIIa (red) and F-actin labeling
with phalloidin (green) demonstrated extensive loss of OHCs in the basal, mid-basal,
and apical portions of cochleae treated with the EP4 antagonist. Scale bar, 20 mm.
(C) A quantitative analysis demonstrated signiﬁcant differences between the two
groups in the numbers of lost OHCs in the apical, mid-basal, and basal portions of
cochleae. Asterisk indicates a signiﬁcant difference (P < 0.05). No signiﬁcant difference
in IHC numbers was found between the two groups. In all graphs, the error bars
represent the SEM. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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the degeneration of OHCs in response to noise. Cochlear specimens
were obtained 14 days after noise exposure. Noise-induced damage
to the organ of Corti was assessed by immunostaining for myosin
VIIa and f-actin labeling with phalloidin in whole-mount prepara-
tions. Minor loss of OHCs was observed in the basal, mid-basal, and
apical portions of wild-type cochleae, whereas the EP4-deﬁcient
mice exhibited extensive loss of OHCs (Fig. 2D). A quantitative
analysis demonstrated signiﬁcant decreases of OHCs in the apical
(P ¼ 0.0058), mid-basal (P ¼ 0.0330), and basal (P ¼ 0.0400)
portions of the cochleae of EP4-deﬁcient mice in comparison with
those of wild-type mice (Fig. 2E). No signiﬁcant difference in inner
hair cells (IHCs) was found between EP4-deﬁcient and wild-type
mice (Fig. 2E). Immunostaining for bIII tubulin in cross sections
revealed no degeneration of spiral ganglion neurons in either
EP4-deﬁcient or wild-type mice (Fig. 2F), and quantitative assess-
ments revealed no signiﬁcant difference in the density of spiral
ganglion neurons between EP4-deﬁcient and wild-type mice (n¼ 4
for each; Fig. 2G). Consequently, morphological differences
between EP4-deﬁcient and wild-type mice also appeared to be
apparent following noise exposure, which suggests that the OHC is
included in targets of cochlear damage due to EP4 deﬁciency. These
ﬁndings demonstrate that EP4-deﬁcient mice are vulnerable to
noise-induced damage in comparison with wild-type animals,
indicating the importance of EP4 for cochlear protection, particu-
larly in OHCs, against noise trauma.
3.3. Inhibition of EP4 signaling enhanced noise-induced cochlear
damage
The pharmacological inhibition of EP4 signaling was investi-
gated in order to conﬁrm the effects of EP4 deﬁciency on noise-
induced hearing loss. The EP4 antagonist ONO-AE3-208
(Kabashima et al., 2002; Sugimoto and Narumiya, 2007) was topi-
cally applied to the RWM in the middle-ear cavity of 8-week-old
C57BL/6 mice. Immediately after the topical application, animals
were exposed to an octave-band noise centered on 8 kHz at 120 dB
SPL for 1 h. Both control and EP4 antagonist-treated animals (n ¼ 5
for each) showed similar elevations of ABR thresholds on day 1 after
noise exposure (Fig. 3A), indicating that both groups experienced
similar levels of initial damage. However, the subsequent recovery
process differed notably between the two groups (Fig. 3A). In
control animals, the ABR-threshold shifts showed a trend toward
recovery at all frequencies, whereas no recovery was observed in
EP4 antagonist-treated animals (Fig. 3A). Statistical analyses
revealed signiﬁcant differences in the ABR-threshold shifts between
the two groups at each frequency. The overall effects of EP4
antagonist applicationwere signiﬁcant at 10 kHz (df ¼ 1, F ¼ 10.195
and P ¼ 0.0032), 20 kHz (df ¼ 1, F ¼ 10.662 and P ¼ 0.0026), and
40 kHz (df ¼ 1, F ¼ 15.703 and P ¼ 0.0004). Pair-wise comparisons
revealed signiﬁcant differences in the ABR-threshold shifts on day 7
at 10 and 20 kHz, and on days 7 and 14 at 40 kHz. These ﬁndings
demonstrate that pharmacological inhibition of EP4 had a similar
effect to genetic deletion in enhancing noise-induced hearing loss.
Morphological assessment demonstrated the enhancement of
noise-induced damage to OHCs caused by pharmacological inhi-
bition of EP4 signaling. Immunostaining for myosin VIIa and f-actin
labeling with phalloidin in whole-mount preparations revealed an
enhancement of OHC loss in the basal, mid-basal, and apical
portions of cochleae by the EP4 antagonist (Fig. 3B). A quantitative
analysis demonstrated signiﬁcantly greater OHC loss in the basal
(P ¼ 0.0473), mid-basal (P ¼ 0.0089), and apical (P ¼ 0.0282)
portions of cochleae treated with the EP4 antagonist (Fig. 3C). By
contrast, no signiﬁcant difference in IHC loss was found between
the two groups (Fig. 3C). These ﬁndings revealed thatpharmacological inhibition of EP4 had a similar effect to genetic
deletion in enhancing OHC degeneration due to noise exposure.
EP4 signalingmight therefore play a role in protecting OHCs against
noise-induced damage.3.4. EP4 agonist attenuated noise-induced cochlear damage
Both genetic deletion and pharmacological inhibition of EP4
enhanced noise-induced damage to cochleae. These ﬁndings sug-
gested that the activation of EP4 signaling could attenuate noise-
induced hearing loss. We tested the effects of the EP4 agonist
ONO-AE1-329 (Sugimoto and Narumiya, 2007; Suzawa et al., 2000)
on noise-induced damage in 8-week-old C57BL/6 mice. Immedi-
ately after drug application, the animals were exposed to an octave-
band noise centered on 8 kHz at 120 dB SPL for 2 h. Control animals
(n ¼ 5) showed ABR-threshold shift of approximately 80 dB on day
7 and no recovery on day 14. The animals treated with the EP4
agonist (n ¼ 5) exhibited comparatively small ABR-threshold shifts
on day 7, and showed a trend for decreasing shifts until day 14
(Fig. 4A). Statistical analyses revealed that local application of the
EP4 agonist had signiﬁcant effects on ABR-threshold shifts at
10 kHz (df¼ 1, F¼ 25.000 and P< 0.0001), 20 kHz (df¼ 1, F¼ 9.164
and P ¼ 0.0058), and 40 kHz (df ¼ 1, F ¼ 36.152 and P < 0.0001).
Pair-wise comparisons showed signiﬁcant differences between the
two groups in ABR-threshold shifts on days 7 and 14 at 10 kHz, on
Fig. 4. The EP4 agonist ameliorated noise-induced damage to cochleae. The EP4
agonist ONO-AE1-329 was locally applied to the RWM and control animals received
a local application of physiological saline containing 1% DMSO. (A) The time courses of
the alterations in the ABR-threshold shifts of EP4 agonist-treated and control mice at
frequencies of 10, 20, and 40 kHz are shown. The overall effects of local application of
the EP4 agonist on ABR-threshold shifts were signiﬁcant at all frequencies. Asterisks
indicate signiﬁcant differences in ABR-threshold shifts between EP4 agonist-treated
and control mice with pair-wise comparisons. (B) Immunostaining for myosin VIIa
(red) and F-actin labeling with phalloidin (green) showed severe loss of OHCs in
control specimens, whereas the morphology of the organ of Corti was preserved in EP4
agonist-treated mice. Scale bar, 20 mm. (C) A quantitative analysis demonstrated
signiﬁcant differences between the two groups in the numbers of lost OHCs in the
apical, mid-basal, and basal portions of cochleae. Asterisk indicates a signiﬁcant
difference (P < 0.05). No signiﬁcant difference in IHC numbers was found between the
two groups. In all graphs, the error bars represent the SEM. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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demonstrate that the topical application of an EP4 agonist attenu-
ated noise-induced hearing loss.
Morphologically, severe degeneration of OHCs was observed
from the apex to the base of cochleae in control animals (Fig. 4B).
Approximately 70% of the OHCs in the mid-basal and basal portions
of cochleae were destroyed by the noise exposure in control
animals (Fig. 4C). In contrast to control animals, OHCs in specimens
treated with the EP4 agonist were well maintained (Fig. 4B).
Quantitative assessments showed that the EP4 agonist had
a signiﬁcant protective effect on OHCs in the apical (P ¼ 0.0209),
mid-basal (P ¼ 0.0215), and basal (P ¼ 0.0455) portions of cochleae
(Fig. 4C). No signiﬁcant difference in IHC loss was found between
the two groups (Fig. 4C). These ﬁndings demonstrate that the
pharmacological activation of EP4 signaling promoted the survival
of OHCs exposed to noise trauma. These ﬁndings in pharmacolog-
ical activation of EP4 support our hypothesis that EP4 signaling
plays a crucial role in the maintenance of auditory function.
4. Discussion
The present study demonstrates that genetic deletion of EP4
causes slight elevation of ABR thresholds and loss of DPOAEs,
although the endocochlear potential is maintained in normal levels.
Genetic deletion of EP4 accelerated ABR-threshold shifts and loss ofDPOAEs, but not of endocochlear potentials, following noise
exposure. These ﬁndings in EP4-deﬁcient mice indicate that EP4
may be involved in the maintenance of auditory function, in
particular OHC function. In addition, pharmacological inhibition of
EP4 signaling enhanced noise-induced hearing loss, and its phar-
macological activation attenuated noise-induced hearing loss.
Findings in pharmacological inhibition or activation support the
ﬁndings in genetic deletion of EP4.
Experimental animals were exposed to an octave-band noise
centered on 8 kHz at a 120-dB SPL, which causes cochlear damage
not only in low frequency regions, but also middle and high
frequency regions (Ou et al., 2000), for 1 or 2 h according to the
experimental design. In experiments of genetic deletion or phar-
macological inhibition of EP4, we intended to induce mild hearing
loss in control animals, which is suitable for assessments of accel-
eration of noise-induced damage by toxic treatments. In genetic
deletion of EP4, 2-h noise exposure was used, while 1-h exposure
was used in pharmacological inhibition of EP4, because of the
difference in back ground strains between two experiments. In
genetic deletion of EP4, a mixed 129/Ola and C57BL/6 genetic
background was used, while in pharmacological inhibition of EP4,
we used C57BL/6 mice, which were reported to be more vulnerable
to noise trauma than sub-strains of mouse strain 129 (Turner et al.,
2005; Yoshida et al., 2000). We therefore used a shorter noise
exposure period in pharmacological inhibition of EP4 than that in
experiments using EP4-deﬁcient mice. In experiments for phar-
macological activation of EP4 signaling, we intended to generate
profound hearing loss in control animals, which is suitable for
assessments of protective effects. C57BL/6 mice were, therefore,
exposed to an octave-band noise centered on 8 kHz at 120 dB SPL
for 2 h, which was longer than that in pharmacological inhibition
experiments. As we expected, profound hearing loss occurred in
control animals, and signiﬁcant protection by pharmacological
activation of EP4 was observed.
The present study reveals that EP4 signaling plays a crucial role
in the protection of OHCs against noise trauma. Extending the
ﬁndings of our previous study that EP4 is expressed in the OHCs of
the mouse cochlea (Hori et al., 2009), EP4 signaling could therefore
act directly on OHCs. The activation of EP4 induces cyclic AMP
production in OHCs, which might help to rescue them from energy
depletion caused by overstimulation in response to excessive noise
exposure. EP4 signaling has been reported to activate anti-
apoptotic pathways associated with protein kinase A (Hoshino
et al., 2003), phosphatidylinositol 3-kinase-mediated AKT phos-
phorylation (Liou et al., 2007), BCL-2 antagonist of cell death (BAD)
(Chun et al., 2007) and survivin (Baratelli et al., 2005). Such
mechanisms could be involved in OHC protection by EP4 signaling
in mouse models of noise-induced hearing loss.
The expression of EP4 was also identiﬁed in a variety of cell
types in the mouse cochlea (Hori et al., 2009). Therefore, indirect
effects of EP4 signaling could contribute to the promotion of the
survival of OHCs. Previously, pharmacological activation of EP4 has
been reported to induce generation of vascular endothelial growth
factor in spiral ganglion neurons (Hori et al., 2010), which may
contribute to the survival of OHCs against noise-induced damage
(Picciotti et al., 2006; Selivanova et al., 2007).
There are some discrepancies between the functional and
morphological ﬁndings in the present study. In EP4-deﬁcient mice
under a physiological condition, slight ABR-threshold shifts were
found, whereas morphological analyses demonstrated essentially
normal morphology of cochleae except for limited loss of OHCs.
C57/BL6mice treatedwith an EP4 antagonist exhibited slight loss of
OHCs, despite of remarkable ABR-threshold shifts following noise
exposure. These ﬁndings suggest that other targets of EP4 signaling
in the cochlea besides OHCs may play a role in hearing loss due to
K. Hamaguchi et al. / Neuropharmacology 62 (2012) 1841e1847 1847EP4 deﬁciency. EP4 expression was also found in IHCs and spiral
ganglion neurons, which are also involved in mechanisms for
noise-induced hearing loss (Pujol and Puel, 1999). Hence, the IHC
and spiral ganglion neuron could contribute to hearing loss due to
genetic deletion or pharmacological inhibition of EP4. However, no
signiﬁcant loss of IHCs or spiral ganglion neurons was found in EP4-
deﬁcient mice under a physiological condition or after noise trauma
in the present study. Therefore, degeneration at the substructural
level might occur in IHCs and spiral ganglion neurons, in particular
in afferent dendrites attached to the base of the IHC, which is
known as a target of noise trauma (Pujol and Puel, 1999). Future
studies using electronmicroscopy are required to elucidate detailed
mechanisms underlying hearing loss due to lack of EP4 signaling.
In conclusion, the present ﬁndings demonstrate an involvement
of EP4 signaling in the maintenance of the auditory system, and of
OHCs in particular. The roles of other PGE receptors, including
EP1e3, in the cochlea should also be determined, in order to
understand the roles of PGE2 signaling in the auditory system. This
could help to identify new targets for cochlear disease therapeutics.
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